Informed Consent and Advance Directives, 6425-6427 [2022-02316]
Download as PDF
lotter on DSK11XQN23PROD with RULES1
Federal Register / Vol. 87, No. 24 / Friday, February 4, 2022 / Rules and Regulations
human factors study that demonstrates
that an intended user can safely use the
device for its intended use.
(7) Device labeling must include the
following:
(i) A prominent statement identifying
the drugs that are compatible with the
device, including the identity and
concentration of those drugs as
appropriate.
(ii) A description of the minimum and
maximum basal rates, minimum and
maximum bolus volumes, and the
increment size for basal and bolus
delivery, or other similarly applicable
information about drug delivery
parameters.
(iii) A description of the pump
accuracy at minimum, intermediate, and
maximum bolus delivery volumes and
the method(s) used to establish bolus
delivery accuracy. For each bolus
volume, pump accuracy shall be
described in terms of the number of
bolus doses measured to be within a
given range as compared to the
commanded volume. An acceptable
accuracy description (depending on the
drug delivered and bolus volume) may
be provided as follows for each bolus
volume tested, as applicable: Number of
bolus doses with volume that is <25
percent, 25 percent to <75 percent, 75
percent to <95 percent, 95 percent to
<105 percent, 105 percent to <125
percent, 125 percent to <175 percent,
175 to 250 percent, and >250 percent of
the commanded amount.
(iv) A description of the pump
accuracy at minimum, intermediate, and
maximum basal delivery rates and the
method(s) used to establish basal
delivery accuracy. For each basal rate,
pump accuracy shall be described in
terms of the amount of drug delivered
after the basal delivery was first
commanded, without a warmup period,
up to various time points. The
information provided must include
typical pump performance, as well as
worst-case pump performance observed
during testing in terms of both overdelivery and under-delivery. An
acceptable accuracy description
(depending on the drug delivered) may
be provided as follows, as applicable:
The total volume delivered 1 hour, 6
hours, and 12 hours after starting
delivery for a typical pump tested, as
well as for the pump that delivered the
least and the pump that delivered the
most at each time point.
(v) A description of delivery hazard
alarm performance, as applicable. For
occlusion alarms, performance shall be
reported at minimum, intermediate, and
maximum delivery rates and volumes.
This description must include the
specification for the longest time period
VerDate Sep<11>2014
16:00 Feb 03, 2022
Jkt 256001
that may elapse before an occlusion
alarm is triggered under each delivery
condition, as well as the typical results
observed during performance testing of
the pumps.
(vi) For wireless connection enabled
devices, a description of the wireless
quality of service required for proper
use of the device.
(vii) For any infusion pumps intended
for multiple patient reuse, instructions
for safely reprocessing the device
between uses.
Dated: January 26, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–02369 Filed 2–3–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF VETERANS
AFFAIRS
38 CFR Part 17
RIN 2900–AQ97
Informed Consent and Advance
Directives
Department of Veterans Affairs.
Interim final rule.
AGENCY:
ACTION:
The Department of Veterans
Affairs (VA) published an interim final
rule amending its regulation regarding
informed consent and advance
directives. In that rulemaking, we
amended the regulation by reorganizing
it and amending language where
necessary to enhance clarity. We also
made changes to facilitate the informed
consent process, the ability to
communicate with patients or
surrogates through available modalities
of communication, and the execution
and witness requirements for a VA
Advance Directive. Before adopting that
interim final rule as final, VA revises
the provision related to which
personnel may be delegated the
responsibility for providing a patient
with information needed for the patient
to make a fully informed consent
decision. Upon further review, VA has
determined that this provision requires
a further change to better clarify roles in
the team-based delivery of care model.
We are providing the public an
opportunity to submit comments solely
on this amendment.
DATES:
Effective date: This interim final rule
is effective February 4, 2022.
Comments due date: Comments must
be received on or before April 5, 2022.
ADDRESSES: Comments may be
submitted through
www.Regulations.gov. Comments
SUMMARY:
PO 00000
Frm 00023
Fmt 4700
Sfmt 4700
6425
received will be available at
regulations.gov for public viewing,
inspection, or copies.
FOR FURTHER INFORMATION CONTACT:
Lucinda Potter, LSW, Acting Director of
Ethics Policy, National Center for Ethics
in Health Care (10ETH), Veterans Health
Administration, 810 Vermont Ave. NW,
Washington, DC 20420; 484–678–5150.
(This is not a toll-free number).
SUPPLEMENTARY INFORMATION: In an
interim final rule published May 27,
2020 (85 FR 31690), we amended 38
CFR 17.32, our regulation addressing
informed consent for treatments and
procedures, by reorganizing it and
amending language where necessary to
enhance clarity. We also made changes
to facilitate the informed consent
process, the ability to communicate
with patients or surrogates through
available modalities of communication,
and the execution and witnessing for a
VA Advance Directive. We amended the
definition of ‘‘practitioner’’ to include
other health care professionals whose
scope of practice agreement or other
formal delineation of job responsibility
specifically permits them to obtain
informed consent, and who are
appropriately trained and authorized to
perform the procedure or to provide the
treatment for which consent is being
obtained.
Under the previous informed consent
rule, the practitioner, who had primary
responsibility for the patient or who
would perform the particular procedure
or provide the treatment, was
responsible for explaining in language
understandable to the patient or
surrogate the nature of a proposed
procedure or treatment; the expected
benefits; reasonably foreseeable
associated risks, complications or side
effects; reasonable and available
alternatives; and anticipated results if
nothing is done. There was no provision
in the rule addressing the question of
whether, consistent with a team-based
delivery of care model, appropriately
trained health care team members had a
role in the informed consent process. In
the May 2020 interim final rule, we
dealt with that issue in paragraph (c)(6),
stating that the practitioner may
delegate to other trained personnel
responsibility for providing the patient
with clinical information needed for the
patient to make a fully informed consent
decision but must personally verify with
the patient that the patient has been
appropriately informed and voluntarily
consents to the treatment or procedure.
VA intended that paragraph (c)(6) give
the practitioner discretion to more fully
utilize the training and expertise of nonpractitioners within the bounds of the
E:\FR\FM\04FER1.SGM
04FER1
lotter on DSK11XQN23PROD with RULES1
6426
Federal Register / Vol. 87, No. 24 / Friday, February 4, 2022 / Rules and Regulations
team-based care model. Upon further
review, VA has determined that this
paragraph should be amended to more
clearly reflect VA’s intent to utilize a
team-based approach for other elements
of informed consent discussions in
addition to provision of information to
the patient. Consistent with
longstanding VA policy and practice,
we amend paragraph (c)(6) to more
broadly state that trained personnel may
conduct elements of the informed
consent process when delegated by the
practitioner.
We are also removing the term
‘‘clinical information’’ in this paragraph.
We believe the term ‘‘clinical
information’’ in the current paragraph
(c)(6) could be problematic. It is not
defined in VA regulations and is used
only in VA policy documents either
generically (to describe any health
information reflected in medical
records) or to describe specific types of
stored information such as medicalrelated data, images, sound, and video
related to certain types of medical
examinations. ‘‘Clinical information’’
could also be narrowly used to describe
only technical information related to a
treatment or procedure. A narrow
construction and application of that
term is counter to the team model which
is intended to benefit the patient by
allowing members of the health care
team to provide necessary information
through different perspectives. This
model also provides the patient an
opportunity to freely communicate with
not only the practitioner but also with
other team members regarding the
proposed treatment or procedure.
Based on that rationale, we amend
paragraph (c)(6) to clarify that the
practitioner may delegate to trained
personnel the responsibility of
conducting elements of the informed
consent process beyond simply
providing information. To ensure that
clinical oversight is retained, the
practitioner remains responsible for the
informed consent process and must
personally verify with the patient that
the patient has been fully informed and
voluntarily consents to the treatment or
procedure. Elements of the informed
consent process that may be delegated
to trained personnel include providing
patient education regarding the
proposed treatment or procedure,
identifying the authorized surrogate for
patients who lack decision-making
capacity, and assisting with obtaining
the patient’s (or surrogate’s) signature
for treatments and procedures that
require signature informed consent.
VA believes that this will ensure that
elements of informed consent
discussions that may be appropriately
VerDate Sep<11>2014
16:00 Feb 03, 2022
Jkt 256001
delegated by providers are not unduly
limited by regulation, while still making
clear that the practitioner remains
responsible for the informed consent
process and for personally verifying
with the patient that the patient has
been fully informed and voluntarily
consents to the treatment or procedure.
We are providing a 60-day period for
submission of comments from the
public on this amendment of
§ 17.32(c)(6). We are not accepting any
public comment on any other content in
§ 17.32. Following the 60-day public
comment period, we will review and
consider comments received and then
publish a final rulemaking capturing not
only this interim final rule but also the
May 2020 interim final rule.
Administrative Procedure Act
The Secretary of Veterans Affairs
finds that there is good cause under the
provisions of 5 U.S.C. 553(b)(B), to
publish this amendment as an interim
final rule without prior notice and the
opportunity for public comment, and
under 5 U.S.C. 553(d)(3), to dispense
with the delayed effective date
ordinarily prescribed by the
Administrative Procedure Act (APA).
Pursuant to section 553(b)(B) of the
APA, general notice and the opportunity
for public comment are not required
with respect to a rulemaking when an
‘‘agency for good cause finds (and
incorporates the finding and a brief
statement of reasons therefor in the
rules issued) that notice and public
procedure thereon are impracticable,
unnecessary, or contrary to the public
interest.’’ The Secretary finds that it is
impractical to delay issuance of this rule
for the purpose of soliciting prior public
comment because there is an immediate
and pressing need for VA to respond to
the current public health crisis and
national emergency by ensuring
effective use of health care resources as
part of the announced VA contingent/
crisis standards of care, in addition to
regular standards of care provided to
eligible beneficiaries. VA believes
members of a VA health care team
should be utilized to the fullest extent
practicable in providing veterans
information on risks and benefits of
proposed treatments or procedures.
Thus, delaying the implementation of
this clarifying amendment would be
contrary to the public interest.
For these reasons, the Secretary has
concluded that ordinary notice and
comment procedures would be both
impracticable and contrary to the public
interest. Accordingly, VA issues this
amendment as a separate interim final
rule. The Secretary will consider and
address comments that are received
PO 00000
Frm 00024
Fmt 4700
Sfmt 4700
within 60 days after the date that this
interim final rule is published in the
Federal Register and address them in a
subsequent Federal Register document
announcing a final rule incorporating
any changes made in response to the
public comments on this interim final
rule and the May 2020 interim final
rule.
The APA also requires a 30-day
delayed effective date, except for ‘‘(1) a
substantive rule which grants or
recognizes an exemption or relieves a
restriction; (2) interpretative rules and
statements of policy; or (3) as otherwise
provided by the agency for good cause
found and published with the rule.’’ 5
U.S.C. 553(d). For the reasons stated
above, the Secretary finds that there is
also good cause for this interim rule to
be effective immediately upon
publication. It is in the public interest
for VA to immediately adopt the process
changes noted above to provide for
effective utilization of VA practitioners
as it relates to the informed consent
process during this period of increased
demand for health care, to provide
flexibility to utilize alternative
modalities of communications during
the COVID–19 National Emergency, and
to facilitate veterans documenting
treatment preferences in an advance
directive. By immediately making
necessary process changes, the Secretary
finds good cause to exempt this
amendment from the APA’s delayed
effective date requirement.
Paperwork Reduction Act
Although this action contains
provisions constituting collections of
information, at 38 CFR 17.32, under the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501–3521), no new or proposed
revised collections of information are
associated with this interim final rule.
The information collection requirements
for § 17.32 are currently approved by the
Office of Management and Budget
(OMB) and have been assigned OMB
control number 2900–0556.
Regulatory Flexibility Act
The Secretary hereby certifies that
this interim final rule will not have a
significant economic impact on a
substantial number of small entities as
they are defined in the Regulatory
Flexibility Act, 5 U.S.C. 601–612,
because it affects only the informed
consent process and use of advance
directives within the VA health care
system.
Therefore, pursuant to 5 U.S.C.
605(b), the initial and final regulatory
flexibility analysis requirements of 5
U.S.C. 603 and 604 do not apply.
E:\FR\FM\04FER1.SGM
04FER1
Federal Register / Vol. 87, No. 24 / Friday, February 4, 2022 / Rules and Regulations
Executive Orders 12866 and 13563
Executive Orders 12866 and 13563
direct agencies to assess the costs and
benefits of available regulatory
alternatives and, when regulation is
necessary, to select regulatory
approaches that maximize net benefits
(including potential economic,
environmental, public health and safety
effects, and other advantages;
distributive impacts; and equity).
Executive Order 13563 (Improving
Regulation and Regulatory Review)
emphasizes the importance of
quantifying both costs and benefits,
reducing costs, harmonizing rules, and
promoting flexibility. The Office of
Information and Regulatory Affairs has
determined that this rule is not a
significant regulatory action under
Executive Order 12866.
The Regulatory Impact Analysis
associated with this rulemaking can be
found as a supporting document at
www.regulations.gov.
Unfunded Mandates
The Unfunded Mandates Reform Act
of 1995 requires, at 2 U.S.C. 1532, that
agencies prepare an assessment of
anticipated costs and benefits before
issuing any rule that may result in the
expenditure by State, local, and tribal
governments, in the aggregate, or by the
private sector, of $100 million or more
(adjusted annually for inflation) in any
one year. The amendment issued here as
an interim final rule will not result in
the expenditure of $100 million or more
by State, local, and tribal governments,
in the aggregate, or by the private sector.
lotter on DSK11XQN23PROD with RULES1
Congressional Review Act
Pursuant to the Congressional Review
Act (5 U.S.C. 801 et seq.), the Office of
Information and Regulatory Affairs
designated this rule as not a major rule,
as defined by 5 U.S.C. 804(2).
Assistance Listing
The Assistance Listing program
numbers and titles for the programs
affected by this document are 64.008—
Veterans Domiciliary Care; 64.011—
Veterans Dental Care; 64.012—Veterans
Prescription Service; 64.013—Veterans
Prosthetic Appliances; 64.014—
Veterans State Domiciliary Care;
64.015—Veterans State Nursing Home
Care; 64.024—VA Homeless Providers
Grant and Per Diem Program; 64.026—
Veterans State Adult Day Health Care;
64.029—Purchase Care Program;
64.039—CHAMPVA; 64.040—VHA
Inpatient Medicine; 64.041—VHA
Outpatient Specialty Care; 64.042—
VHA Inpatient Surgery; 64.043—VHA
Mental Health Residential; 64.044—
VHA Home Care; 64.045—VHA
VerDate Sep<11>2014
16:00 Feb 03, 2022
Jkt 256001
Outpatient Ancillary Services; 64.046—
VHA Inpatient Psychiatry; 64.047—
VHA Primary Care; 64.048—VHA
Mental Health clinics; 64.049—VHA
Community Living Center; 64.050—
VHA Diagnostic Care; 64.054—Research
and Development.
List of Subjects in 38 CFR Part 17
Administrative practice and
procedure, Alcohol abuse, Alcoholism,
Claims, Day care, Dental health, Drug
abuse, Government contracts, Grant
programs—health, Grant programs—
veterans, Health care, Health facilities,
Health professions, Health records,
Homeless, Medical and Dental schools,
Medical devices, Medical research,
Mental health programs, Nursing
homes, Reporting and recordkeeping
requirements, Travel and transportation
expenses, Veterans.
Signing Authority
Denis McDonough, Secretary of
Veterans Affairs, approved this
document on January 31, 2022, and
authorized the undersigned to sign and
submit the document to the Office of the
Federal Register for publication
electronically as an official document of
the Department of Veterans Affairs.
Consuela Benjamin,
Regulation Development Coordinator, Office
of Regulation Policy & Management, Office
of General Counsel, Department of Veterans
Affairs.
For the reasons set out in the
preamble, VA amends 38 CFR part 17 as
follows:
PART 17—MEDICAL
1. The authority citation for part 17
continues to read as follows:
■
Authority: 38 U.S.C. 501, and as noted in
specific sections.
2. Amend § 17.32 by revising
paragraph (c)(6) to read as follows:
■
§ 17.32 Informed consent and advance
directives.
*
*
*
*
*
(c) * * *
(6) Trained personnel may conduct
elements of the informed consent
process when delegated by the
practitioner. However, the practitioner
remains responsible for the informed
consent process and must personally
verify with the patient that the patient
has been fully informed and voluntarily
consents to the treatment or procedure.
*
*
*
*
*
[FR Doc. 2022–02316 Filed 2–3–22; 8:45 am]
BILLING CODE 8320–01–P
PO 00000
Frm 00025
Fmt 4700
Sfmt 4700
6427
DEPARTMENT OF VETERANS
AFFAIRS
38 CFR Part 21
Clarification Concerning Tuition and
Fees Payment Plans for Standard
Terms and 85/15 Calculations
Department of Veterans Affairs.
Policy interpretation.
AGENCY:
ACTION:
The Department of Veterans
Affairs (VA) provides notice of a policy
advisory issued on August 31, 2021, by
VA’s Education Service. The policy
advisory clarifies and amends VA’s
previous regulatory interpretation of
tuition and fees (T&F) payment plans to
differentiate between types of payment
plans. Some payment plans should no
longer be categorized as institutional
support to a student when calculating
the ratio of ‘‘supported’’ to ‘‘nonsupported’’ students in a program
pursuant to the 85/15 Rule. While VA
is retaining the general rule that a
student who has a payment plan with
an Educational Training Institute (ETI)
should be considered supported, a
student participating in a payment plan
that meets the criteria set forth in this
notice should not be considered
supported and, instead, should be
counted on the non-supported side of
the 85/15 ratio.
DATES: This policy interpretation is
applicable from February 4, 2022.
FOR FURTHER INFORMATION CONTACT:
Cheryl Amitay, Chief of Policy and
Regulations Team, Education Service
(225), Veterans Benefits Administration,
Department of Veterans Affairs, 810
Vermont Avenue NW, Washington, DC
20420, Telephone: 202–461–9800 (This
is not a toll-free number).
SUPPLEMENTARY INFORMATION: The 85/15
rule (38 U.S.C. 3680A(d); 38 CFR
21.4201(a)) prohibits VA from paying
educational assistance benefits to any
new students once ‘‘more than 85
percent of the students enrolled in the
[program of education] are having all or
part of their tuition, fees or other
charges paid to or for them by the
educational institution or by the
Department of Veterans Affairs’’ (38
U.S.C. 3680A(d)(1)). VA refers to
students who receive such institutional
or VA aid as ‘‘supported’’ students.
Conversely, no less than 15 percent of
the students enrolled in the program
must be attending without having any of
their tuition, fees or other charges paid
to or for them by the educational
institution or VA (referred to as nonsupported students).
Currently, in accordance with 38 CFR
21.4201, educational institutions are
SUMMARY:
E:\FR\FM\04FER1.SGM
04FER1
Agencies
[Federal Register Volume 87, Number 24 (Friday, February 4, 2022)]
[Rules and Regulations]
[Pages 6425-6427]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02316]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF VETERANS AFFAIRS
38 CFR Part 17
RIN 2900-AQ97
Informed Consent and Advance Directives
AGENCY: Department of Veterans Affairs.
ACTION: Interim final rule.
-----------------------------------------------------------------------
SUMMARY: The Department of Veterans Affairs (VA) published an interim
final rule amending its regulation regarding informed consent and
advance directives. In that rulemaking, we amended the regulation by
reorganizing it and amending language where necessary to enhance
clarity. We also made changes to facilitate the informed consent
process, the ability to communicate with patients or surrogates through
available modalities of communication, and the execution and witness
requirements for a VA Advance Directive. Before adopting that interim
final rule as final, VA revises the provision related to which
personnel may be delegated the responsibility for providing a patient
with information needed for the patient to make a fully informed
consent decision. Upon further review, VA has determined that this
provision requires a further change to better clarify roles in the
team-based delivery of care model. We are providing the public an
opportunity to submit comments solely on this amendment.
DATES:
Effective date: This interim final rule is effective February 4,
2022.
Comments due date: Comments must be received on or before April 5,
2022.
ADDRESSES: Comments may be submitted through www.Regulations.gov.
Comments received will be available at regulations.gov for public
viewing, inspection, or copies.
FOR FURTHER INFORMATION CONTACT: Lucinda Potter, LSW, Acting Director
of Ethics Policy, National Center for Ethics in Health Care (10ETH),
Veterans Health Administration, 810 Vermont Ave. NW, Washington, DC
20420; 484-678-5150. (This is not a toll-free number).
SUPPLEMENTARY INFORMATION: In an interim final rule published May 27,
2020 (85 FR 31690), we amended 38 CFR 17.32, our regulation addressing
informed consent for treatments and procedures, by reorganizing it and
amending language where necessary to enhance clarity. We also made
changes to facilitate the informed consent process, the ability to
communicate with patients or surrogates through available modalities of
communication, and the execution and witnessing for a VA Advance
Directive. We amended the definition of ``practitioner'' to include
other health care professionals whose scope of practice agreement or
other formal delineation of job responsibility specifically permits
them to obtain informed consent, and who are appropriately trained and
authorized to perform the procedure or to provide the treatment for
which consent is being obtained.
Under the previous informed consent rule, the practitioner, who had
primary responsibility for the patient or who would perform the
particular procedure or provide the treatment, was responsible for
explaining in language understandable to the patient or surrogate the
nature of a proposed procedure or treatment; the expected benefits;
reasonably foreseeable associated risks, complications or side effects;
reasonable and available alternatives; and anticipated results if
nothing is done. There was no provision in the rule addressing the
question of whether, consistent with a team-based delivery of care
model, appropriately trained health care team members had a role in the
informed consent process. In the May 2020 interim final rule, we dealt
with that issue in paragraph (c)(6), stating that the practitioner may
delegate to other trained personnel responsibility for providing the
patient with clinical information needed for the patient to make a
fully informed consent decision but must personally verify with the
patient that the patient has been appropriately informed and
voluntarily consents to the treatment or procedure.
VA intended that paragraph (c)(6) give the practitioner discretion
to more fully utilize the training and expertise of non-practitioners
within the bounds of the
[[Page 6426]]
team-based care model. Upon further review, VA has determined that this
paragraph should be amended to more clearly reflect VA's intent to
utilize a team-based approach for other elements of informed consent
discussions in addition to provision of information to the patient.
Consistent with longstanding VA policy and practice, we amend paragraph
(c)(6) to more broadly state that trained personnel may conduct
elements of the informed consent process when delegated by the
practitioner.
We are also removing the term ``clinical information'' in this
paragraph. We believe the term ``clinical information'' in the current
paragraph (c)(6) could be problematic. It is not defined in VA
regulations and is used only in VA policy documents either generically
(to describe any health information reflected in medical records) or to
describe specific types of stored information such as medical-related
data, images, sound, and video related to certain types of medical
examinations. ``Clinical information'' could also be narrowly used to
describe only technical information related to a treatment or
procedure. A narrow construction and application of that term is
counter to the team model which is intended to benefit the patient by
allowing members of the health care team to provide necessary
information through different perspectives. This model also provides
the patient an opportunity to freely communicate with not only the
practitioner but also with other team members regarding the proposed
treatment or procedure.
Based on that rationale, we amend paragraph (c)(6) to clarify that
the practitioner may delegate to trained personnel the responsibility
of conducting elements of the informed consent process beyond simply
providing information. To ensure that clinical oversight is retained,
the practitioner remains responsible for the informed consent process
and must personally verify with the patient that the patient has been
fully informed and voluntarily consents to the treatment or procedure.
Elements of the informed consent process that may be delegated to
trained personnel include providing patient education regarding the
proposed treatment or procedure, identifying the authorized surrogate
for patients who lack decision-making capacity, and assisting with
obtaining the patient's (or surrogate's) signature for treatments and
procedures that require signature informed consent.
VA believes that this will ensure that elements of informed consent
discussions that may be appropriately delegated by providers are not
unduly limited by regulation, while still making clear that the
practitioner remains responsible for the informed consent process and
for personally verifying with the patient that the patient has been
fully informed and voluntarily consents to the treatment or procedure.
We are providing a 60-day period for submission of comments from
the public on this amendment of Sec. 17.32(c)(6). We are not accepting
any public comment on any other content in Sec. 17.32. Following the
60-day public comment period, we will review and consider comments
received and then publish a final rulemaking capturing not only this
interim final rule but also the May 2020 interim final rule.
Administrative Procedure Act
The Secretary of Veterans Affairs finds that there is good cause
under the provisions of 5 U.S.C. 553(b)(B), to publish this amendment
as an interim final rule without prior notice and the opportunity for
public comment, and under 5 U.S.C. 553(d)(3), to dispense with the
delayed effective date ordinarily prescribed by the Administrative
Procedure Act (APA).
Pursuant to section 553(b)(B) of the APA, general notice and the
opportunity for public comment are not required with respect to a
rulemaking when an ``agency for good cause finds (and incorporates the
finding and a brief statement of reasons therefor in the rules issued)
that notice and public procedure thereon are impracticable,
unnecessary, or contrary to the public interest.'' The Secretary finds
that it is impractical to delay issuance of this rule for the purpose
of soliciting prior public comment because there is an immediate and
pressing need for VA to respond to the current public health crisis and
national emergency by ensuring effective use of health care resources
as part of the announced VA contingent/crisis standards of care, in
addition to regular standards of care provided to eligible
beneficiaries. VA believes members of a VA health care team should be
utilized to the fullest extent practicable in providing veterans
information on risks and benefits of proposed treatments or procedures.
Thus, delaying the implementation of this clarifying amendment would be
contrary to the public interest.
For these reasons, the Secretary has concluded that ordinary notice
and comment procedures would be both impracticable and contrary to the
public interest. Accordingly, VA issues this amendment as a separate
interim final rule. The Secretary will consider and address comments
that are received within 60 days after the date that this interim final
rule is published in the Federal Register and address them in a
subsequent Federal Register document announcing a final rule
incorporating any changes made in response to the public comments on
this interim final rule and the May 2020 interim final rule.
The APA also requires a 30-day delayed effective date, except for
``(1) a substantive rule which grants or recognizes an exemption or
relieves a restriction; (2) interpretative rules and statements of
policy; or (3) as otherwise provided by the agency for good cause found
and published with the rule.'' 5 U.S.C. 553(d). For the reasons stated
above, the Secretary finds that there is also good cause for this
interim rule to be effective immediately upon publication. It is in the
public interest for VA to immediately adopt the process changes noted
above to provide for effective utilization of VA practitioners as it
relates to the informed consent process during this period of increased
demand for health care, to provide flexibility to utilize alternative
modalities of communications during the COVID-19 National Emergency,
and to facilitate veterans documenting treatment preferences in an
advance directive. By immediately making necessary process changes, the
Secretary finds good cause to exempt this amendment from the APA's
delayed effective date requirement.
Paperwork Reduction Act
Although this action contains provisions constituting collections
of information, at 38 CFR 17.32, under the Paperwork Reduction Act of
1995 (44 U.S.C. 3501-3521), no new or proposed revised collections of
information are associated with this interim final rule. The
information collection requirements for Sec. 17.32 are currently
approved by the Office of Management and Budget (OMB) and have been
assigned OMB control number 2900-0556.
Regulatory Flexibility Act
The Secretary hereby certifies that this interim final rule will
not have a significant economic impact on a substantial number of small
entities as they are defined in the Regulatory Flexibility Act, 5
U.S.C. 601-612, because it affects only the informed consent process
and use of advance directives within the VA health care system.
Therefore, pursuant to 5 U.S.C. 605(b), the initial and final
regulatory flexibility analysis requirements of 5 U.S.C. 603 and 604 do
not apply.
[[Page 6427]]
Executive Orders 12866 and 13563
Executive Orders 12866 and 13563 direct agencies to assess the
costs and benefits of available regulatory alternatives and, when
regulation is necessary, to select regulatory approaches that maximize
net benefits (including potential economic, environmental, public
health and safety effects, and other advantages; distributive impacts;
and equity). Executive Order 13563 (Improving Regulation and Regulatory
Review) emphasizes the importance of quantifying both costs and
benefits, reducing costs, harmonizing rules, and promoting flexibility.
The Office of Information and Regulatory Affairs has determined that
this rule is not a significant regulatory action under Executive Order
12866.
The Regulatory Impact Analysis associated with this rulemaking can
be found as a supporting document at www.regulations.gov.
Unfunded Mandates
The Unfunded Mandates Reform Act of 1995 requires, at 2 U.S.C.
1532, that agencies prepare an assessment of anticipated costs and
benefits before issuing any rule that may result in the expenditure by
State, local, and tribal governments, in the aggregate, or by the
private sector, of $100 million or more (adjusted annually for
inflation) in any one year. The amendment issued here as an interim
final rule will not result in the expenditure of $100 million or more
by State, local, and tribal governments, in the aggregate, or by the
private sector.
Congressional Review Act
Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.),
the Office of Information and Regulatory Affairs designated this rule
as not a major rule, as defined by 5 U.S.C. 804(2).
Assistance Listing
The Assistance Listing program numbers and titles for the programs
affected by this document are 64.008--Veterans Domiciliary Care;
64.011--Veterans Dental Care; 64.012--Veterans Prescription Service;
64.013--Veterans Prosthetic Appliances; 64.014--Veterans State
Domiciliary Care; 64.015--Veterans State Nursing Home Care; 64.024--VA
Homeless Providers Grant and Per Diem Program; 64.026--Veterans State
Adult Day Health Care; 64.029--Purchase Care Program; 64.039--CHAMPVA;
64.040--VHA Inpatient Medicine; 64.041--VHA Outpatient Specialty Care;
64.042--VHA Inpatient Surgery; 64.043--VHA Mental Health Residential;
64.044--VHA Home Care; 64.045--VHA Outpatient Ancillary Services;
64.046--VHA Inpatient Psychiatry; 64.047--VHA Primary Care; 64.048--VHA
Mental Health clinics; 64.049--VHA Community Living Center; 64.050--VHA
Diagnostic Care; 64.054--Research and Development.
List of Subjects in 38 CFR Part 17
Administrative practice and procedure, Alcohol abuse, Alcoholism,
Claims, Day care, Dental health, Drug abuse, Government contracts,
Grant programs--health, Grant programs--veterans, Health care, Health
facilities, Health professions, Health records, Homeless, Medical and
Dental schools, Medical devices, Medical research, Mental health
programs, Nursing homes, Reporting and recordkeeping requirements,
Travel and transportation expenses, Veterans.
Signing Authority
Denis McDonough, Secretary of Veterans Affairs, approved this
document on January 31, 2022, and authorized the undersigned to sign
and submit the document to the Office of the Federal Register for
publication electronically as an official document of the Department of
Veterans Affairs.
Consuela Benjamin,
Regulation Development Coordinator, Office of Regulation Policy &
Management, Office of General Counsel, Department of Veterans Affairs.
For the reasons set out in the preamble, VA amends 38 CFR part 17
as follows:
PART 17--MEDICAL
0
1. The authority citation for part 17 continues to read as follows:
Authority: 38 U.S.C. 501, and as noted in specific sections.
0
2. Amend Sec. 17.32 by revising paragraph (c)(6) to read as follows:
Sec. 17.32 Informed consent and advance directives.
* * * * *
(c) * * *
(6) Trained personnel may conduct elements of the informed consent
process when delegated by the practitioner. However, the practitioner
remains responsible for the informed consent process and must
personally verify with the patient that the patient has been fully
informed and voluntarily consents to the treatment or procedure.
* * * * *
[FR Doc. 2022-02316 Filed 2-3-22; 8:45 am]
BILLING CODE 8320-01-P